Document is current

Any future updates will be listed below

A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer’s Disease in Taiwan

Crossref DOI link: https://doi.org/10.1007/s12325-019-00939-0

Published Online: 2019-04-05

Published Print: 2019-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark